Abstract
Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5mg/day.
Lingua originale | English |
---|---|
pagine (da-a) | 165-169 |
Numero di pagine | 5 |
Rivista | Clinical Neurophysiology |
Volume | 126 |
DOI | |
Stato di pubblicazione | Pubblicato - 2015 |
Keywords
- Administration, Oral
- Adult
- Animals
- Evoked Potentials, Motor
- Female
- Fingolimod
- Fingolimod Hydrochloride
- Glutamate
- Glutamic Acid
- Humans
- Immunosuppressive Agents
- Intracortical facilitation
- Male
- Middle Aged
- Motor Cortex
- Motor cortex
- Multiple Sclerosis, Relapsing-Remitting
- Multiple sclerosis
- Propylene Glycols
- Prospective Studies
- Sphingosine
- Transcranial Magnetic Stimulation
- Transcranial magnetic stimulation